14-Aug-2026
Immunome (IMNM) Receives a Buy from Guggenheim
TipRanks (Thu, 13-Aug 7:18 AM ET)
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
TipRanks (Wed, 12-Aug 10:05 AM ET)
Evercore ISI Remains a Buy on Immunome (IMNM)
TipRanks (Wed, 12-Aug 9:46 AM ET)
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM)
TipRanks (Wed, 12-Aug 9:40 AM ET)
TipRanks (Wed, 12-Aug 7:40 AM ET)
Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)
TipRanks (Wed, 12-Aug 7:07 AM ET)
TipRanks (Wed, 12-Aug 6:35 AM ET)
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM) and Immunocore Holdings (IMCR)
TipRanks (Wed, 12-Aug 6:20 AM ET)
Barclays Sticks to Its Buy Rating for Immunome (IMNM)
TipRanks (Wed, 12-Aug 5:15 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 12-Aug 1:30 AM ET)
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of August 14, 2026, IMNM stock price climbed to $27.20 with 682,097 million shares trading.
IMNM has a beta of 0.96, meaning it tends to be less sensitive to market movements. IMNM has a correlation of 0.05 to the broad based SPY ETF.
IMNM has a market cap of $3.09 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.65 earnings per share. This fell short of revenue expectation by $-533,336 and missed earnings estimates by -$.14.
In the last 3 years, IMNM traded as high as $30.96 and as low as $5.15.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): XBI, IWM, VTI, IWO, VXF.
IMNM has outperformed the market in the last year with a price return of +173.6% while the SPY ETF gained +21.5%. IMNM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.5% and +19.5%, respectively, while the SPY returned +4.0% and +3.9%, respectively.
IMNM support price is $25.38 and resistance is $27.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.